No new MDMA NDA has been filed with the safety supplements the FDA review process would require. The massed exposure therapy data from military-adjacent trials exists and is promising — a peer-reviewed publication is estimated at 73% probability within six months, likely to surface in Congressional PTSD testimony shortly thereafter — but the pathway from promising data to approval is not a straight line. It runs through an advisory committee that has not yet reconvened, through safety supplement packages that have not yet been filed, through a political environment that is watching this field with eyes that are simultaneously drawn toward it and wary of it. The 78% forecast holds: MDMA-assisted therapy does not receive FDA approval in 2026.
What is forming beneath all of this is a moment of structural clarification — painful, necessary, and not without its own kind of grace. The psychedelic industry built its first chapter on the force of idea: the story was so compelling, the early data so striking, that capital followed vision. What is happening now is that the field is being asked to build its second chapter on something harder to narrative around — sustained execution, regulatory craft, financial discipline, and the slow accumulation of safety evidence that agencies and payers will actually accept. The consolidation pressure is not a refutation of the field's promise. It is the field being asked to prove that the promise is structurally real.
The human beings inside this story are sitting with something difficult to hold. Veterans who enrolled in MDMA trials — who experienced, in many accounts, the first genuine relief from PTSD they had known in years — are watching a regulatory clock that does not move at the speed of their suffering. Families with treatment-resistant depression are waiting for psilocybin pathways that are forming but not yet open. At the same time, retreat-goers in unregulated settings are carrying real risk that the current safety infrastructure was not designed to contain. The highest positive outcome for all of them runs through the same narrow corridor: rigorous safety data that earns genuine institutional trust, regulatory frameworks that are demanding without being obstructive, and a field mature enough to survive the compression it is now inside. That corridor is genuinely open. It requires the field to do the hardest thing — to move at the speed of evidence rather than the speed of hope.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
The medicine is older than the fear. The healing is older than the wound.
82%
MDMA therapy won't get FDA approval in 2026; company must start over
The FDA rejected MDMA-assisted therapy in 2024 because the research had serious problems—like therapists knowing who got the real drug. The company would need to run a new, better-designed study to reapply. Without that work already underway, approval this year is extremely unlikely.
→ MDMA-assisted therapy needs a do-over study, not just paperwork fixes, which makes 2026 approval nearly impossible.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
MDMA-assisted therapy will not receive FDA approval in 2026; any NDA re-engagement will result in a resubmission pathway requiring additional safety data.. No new NDA has been filed with adequate safety supplements as of May 2026. The FDA's Complete Response Letter from 2024 cited fundamental deficiencies in trial design and safety data. Political pressure from veterans advocacy groups is insufficient to override scientific review standards. The FDA's
64%
FDA will update ketamine therapy safety warnings or instructions for doctors by February 2027
Esketamine (Spravato) is a ketamine-based drug the FDA approved for depression, but doctors are now using it off-label (not as approved) to treat suicidal crises in emergency departments without the careful monitoring the FDA required. The FDA monitors real-world safety and will eventually issue a warning letter or instruction update telling doctors how to use it safely, or warning them not to use it in emergency settings where monitoring isn't possible.
→ The FDA will issue new safety instructions for esketamine use by early 2027 because doctors are using it in emergency rooms without proper monitoring.
Resolves: 2027-02-27 · USA
REGULATORY
the precise call ▾
FDA will issue a formal REMS update or Dear Healthcare Provider letter for esketamine (Spravato) citing ED suicidality utilization safety signals by February 2027.. Post-market safety obligations under PDUFA require FDA to respond to emergent real-world utilization data. Published data on off-label esketamine use in ED settings for acute suicidality — outside the controlled REMS monitoring environment — creates a documented safety signal FDA cannot ignore witho
72%
DEA will shut down at least two unregulated psychedelic retreat operators before September 2026
Someone has already died at an unregulated retreat using toad venom (a powerful psychedelic extracted from toads). This death gives the DEA (Drug Enforcement Administration) both a public safety reason and political cover to arrest operators running illegal psychedelic retreats, especially in cities where psilocybin has been decriminalized but not legalized.
→ The DEA will use recent deaths to justify cracking down on unlicensed retreat operators, making unregulated psychedelic experiences legally dangerous.
Resolves: 2026-09-30 · USA
POLICY
the precise call ▾
DEA will initiate at least 2 publicly documented enforcement actions against unregulated psychedelic retreat operators in the US before end of September 2026.. A high-profile toad venom (5-MeO-DMT) death provides DEA with a concrete public safety predicate and Congressional cover to act. DEA has existing Schedule I statutory authority over psilocybin, DMT, and 5-MeO-DMT. Unregulated retreats operating openly in post-decriminalization cities present an enfo
68%
Congress will hold hearings on unregulated retreat safety after a publicized death
A fatality at an illegal psychedelic retreat will force Congressional committees to hold a public hearing demanding answers about why unregulated operations can operate openly. Both lawmakers worried about veteran access and those focused on public safety will use the death as a reason to demand action—one side pushing for legal access, the other for stricter enforcement.
→ A death at an unregulated retreat will trigger Congressional hearings on retreat safety by end of 2026.
Resolves: 2026-12-31 · USA
POLICY
the precise call ▾
Congressional testimony specifically addressing safety standards at unregulated psychedelic retreat operations will occur before end of 2026, triggered by at least one publicized participant death.. The toad venom death case is the predicate event. Congressional oversight committees (Judiciary or Health) respond to high-visibility constituent harms with hearings. The psychedelic space has sufficient political salience — both from veteran advocates pushing access and from safety opponents — to g
71%
At least one struggling psychedelic company will explore mergers before end of Q3 2026
Two major psychedelic biotech companies (COMPASS and Mind Medicine) trade at rock-bottom stock prices with no approval in sight and shrinking cash. When boards see money running out and no good news coming, they typically announce they're 'exploring strategic options'—which usually means merger talks, asset sales, or shutdown. This is the standard corporate signal for desperation.
→ A low-priced psychedelic biotech company will announce it's exploring mergers or partnerships because it's running out of money and investors.
Resolves: 2026-09-30 · Global
MARKET
the precise call ▾
At least one psychedelic biotech company trading below $15/share as of May 2026 will publicly announce a strategic review, merger exploration, or distressed partnership by Q3 2026.. CMPS (~$11.89) and MMED (~$10.96) are both cash-burning without near-term approval catalysts following the MDMA CRL. Board fiduciary duty and institutional investor pressure create structural incentives for strategic review announcements at this valuation level. The 12-month cash runway threshold fo